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Metformin use in type 2 diabetic patients is not
associatedwith lower arterial stiffness: the
Maastricht Study
Johanna H.M. Driessena,b,c,d, Frank de Vriesa,c,d,e, Hein A.W. van Onzenoortc,f,
Miranda T. Schramg,h, Carla van der Kalleng,h, Koen D. Reesinki,j, Simone Sepg,h,
Coen D.A. Stehouwerg,h, Nicolaas Schaperg,h, A.A. Kroong,h, Casper Schalkwijkg,h,
Joop P.W. van den Berghk,l,m, and Ronald M.A. Henryg,h,j
Introduction: Type 2 diabetes (T2D) is associated with
cardiovascular disease complications such as myocardial
infarction and stroke. These complications are at least
partially the consequence of diabetes-associated increased
arterial stiffness. Metformin, a first choice oral glucose-
lowering drug, has been associated with potential cardio-
protective effects. However, there are no data on the
association between real-life metformin use and arterial
stiffness. The objective of the current study is to
investigate in a population-based sample of individuals
with T2D the association between metformin use and
aortic stiffness (i.e. carotid–femoral pulse wave velocity,
cfPWV) and carotid stiffness [i.e. carotid distensibility
coefficient and Young’s elastic modulus (YEM)].
Methods: We used data from The Maastricht Study, an
ongoing observational prospective population-based cohort
study (current N¼3451). All participants with T2D, based
on pharmacy records (N¼672, 31.3% women, mean age
62.67.7), were included in the current study. Linear
regression analyses were used to study the association
between current metformin use and cfPWV, distensibility
coefficient and YEM, as compared with no metformin use.
Furthermore, metformin use was stratified by cumulative
dose (in grams), continuous duration of use (in days),
average daily dose (in grams) and time since first
prescription (in years). Regression coefficients of
distensibility coefficient were multiplied by 1,
consequently, for all arterial stiffness indices, a positive
regression coefficient signifies increasing arterial stiffness.
Results: Linear regression showed that neither current
metformin use was associated with cfPWV [adjusted B:
0.04 (0.11 to 0.02)] nor metformin use was as
stratified by cumulative dose, by continuous duration of
use, by average daily dose or by time since first
prescription. Metformin use was statistically significantly
associated with higher carotid stiffness as assessed by
distensibility coefficient [0.12 (0.01 to 0.23)], but not with
YEM [0.10 (0.03 to 0.22)]. However, there was no
consistent pattern with the different stratifications of
metformin use when further investigating the association
with distensibility coefficient.
Conclusion: We showed that there is no significant
association between current metformin use and aortic
stiffness, regardless of how metformin use in itself was
defined. In addition, metformin use was not associated
with a lower carotid stiffness. The present results showed
no beneficial effect of metformin use, dosage or duration
on arterial stiffness in middle-aged patients with T2D.
Alternatively, metformin may exerts its cardio-protective
effects via other pathways.
Keywords: carotid artery, distensibility, metformin use,
pulse wave velocity
Abbreviations: AGE, advanced glycation end-product;
ATC, anatomical therapeutical chemical; cfPWV, carotid–
femoral pulse wave velocity; CVD, cardiovascular disease;
DDD, defined daily dosage; HbA1c, glycated haemoglobin
A1c; MAP, mean arterial pressure; T2D, type 2 diabetes;
YEM, Young’s elastic modulus
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INTRODUCTION
I
n the year 2030, 439 million individuals will suffer from
type 2 diabetes (T2D), which will be followed by an
epidemic of related cardiovascular disease (CVD) com-
plications such as myocardial infarction (MI) and stroke [1].
These complications are, at least partially, the consequence
of increased arterial stiffness [2–4], as increased arterial
stiffness ultimately leads to increased SBP and decreased
DBP, which hampers coronary perfusion and increases
the pulsatile pressure load on the cerebral (micro-)circula-
tion [5].
The oral glucose-lowering drug metformin is a first
choice therapeutic agent in the treatment of T2D [6]. Inter-
estingly, it has been suggested that metformin use may
protect against CVD. One pathway via which metformin use
may reduce CVD is via an effect on arterial stiffness [7–12].
However, how metformin may do so remains largely
unknown. It has been suggested that metformin interferes
with the formation of advanced glycation end-products
(AGEs), thereby preventing cross-linkage of the pressure
load-bearing elements of the arterial wall by AGEs [2,13,14].
Alternatively, it has been suggested that metformin may
interfere with endothelial dysfunction, chronic low-grade
inflammation and/or increased oxidative stress [6,15].
These phenomena are all associated with increased arterial
stiffness. Currently, there are no data in the population at
large on the association between metformin use and arterial
stiffness, including both aortic and carotid stiffness.
In view of the above, we set out to investigate in a
population-based sample of individuals with T2D the asso-
ciation between metformin use and aortic stiffness (i.e.
carotid–femoral pulse wave velocity, cfPWV) and carotid
stiffness [i.e. carotid distensibility coefficient and Young’s
elastic modulus (YEM)]. Metformin use (yes versus no) was
further stratified according to cumulative dose (in grams),
continuous duration of use (in days), average daily dose (in
grams) and time since first prescription (in years). We
compared metformin use with nonuse.
METHODS
We used data from The Maastricht Study, an observational
prospective population-based cohort study. The rationale
and methodology have been described elsewhere [16]. In
brief, the study focuses on the cause, pathophysiology,
complications and comorbidities of T2D and is character-
ized by an extensive phenotyping approach. Eligible for
participation were all individuals aged between 40 and 75
years and living in the southern part of the Netherlands.
Participants were recruited through mass media campaigns
and from the municipal registries and the regional Diabetes
Patient Registry via mailings. Recruitment was stratified
according to known T2D status, with an oversampling of
individuals with T2D, for reasons of efficiency.
To investigate the association between metformin use
and arterial stiffness we included all participants with T2D,
enrolled between November 2010 and September 2013,
and for whom pharmacy data was available (N¼ 672).
Pharmacy data were available up to the date of the first
visit at the Maastricht Study. Patients were classified as
having T2D if they had a dispensing of an antihyperglyce-
mic drug [anatomical therapeutical chemical (ATC) A10 [17]]
in the 6 months before the first visit (patients with type 1
diabetes mellitus were excluded). Based on the pharmacy
dispensing data patients were classified as a current met-
formin or nonmetformin user. Current metformin users
were initially selected as having at least one metformin
dispensing in 6 months prior to the first study visit accord-
ing to pharmacy dispensing records.
The examinations of each participant were performed
within a time window of 3 months. The cfPWV measure-
ments were performed during the second visit, which was
for the majority of the patients within 8–14 days after their
first visit. The study has been approved by the institutional
medical ethical committee (NL31329.068.10) and the Min-
ister of Health, Welfare and Sports of the Netherlands
(Permit 131088-105234-PG). All participants gave written
informed consent.
Pharmacy dispensing records
Dispensing records were collected at 25 loco-regional
pharmacies for all participants who gave written informed
consent for the collection of their drug dispensing history.
Dispensing data (available from 1 January 1991) contained
product name, ATC code [17], amount and date dispensed,
and the prescribed dosage regimen. For current metformin
users all prescriptions before the first study visit were
extracted. For every prescription, the total amount of
defined daily dosage (DDD) was calculated. If the DDD
could not be calculated the median DDD was assigned
(0.07% of the prescriptions). The cumulative dose was
estimated by adding all prescribed doses of metformin
(in DDDs). The average daily dose was determined as
the cumulative amount of DDDs divided by the time
between the first metformin prescription and the date of
the study visit. To determine the continuous duration of use
we calculated the expected end date for every metformin
prescription by dividing the total number of prescribed
tablets over the number of tablets prescribed per day and
adding this to the dispensing date. When the expected
end date could not be estimated the median duration
was added to determine the expected end date. A gap of
30 days between the estimated end date of a prescription
and the date of the next prescription was allowed for a
prescription to count as continuous use [18]. Continuous
duration of use was then defined as the time between the
first prescription that fulfilled this criteria and the date of the
first study visit.
Arterial stiffness measurements
All measurements were done by trained vascular technicians
unaware of the participants’ clinical or diabetes status, in a
dark, quiet temperature controlled room (21–23 8C). Partic-
ipants were asked to refrain from smoking and drinking
coffee or tea or alcoholic beverages 3h prior to the study.
Participants were allowed to have a light meal [breakfast
and(or) lunch]. All measurements were performed in supine
position after 10min of rest. Talking or sleeping was not
allowed during the examination. During the vascular meas-
urements (approximately 45min), brachial systolic, diastolic,
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and mean arterial pressure (MAP) were determined every
5min with an oscillometric device (Accutorr Plus; Datascope
Inc., Montvale, New Jersey, USA). A three-lead ECG was
recorded continuously during the measurements to facilitate
automatic signal processing.
Carotid-to-femoral pulse wave velocity
cfPWV was determined according to recent guidelines [19]
with the use of applanation tonometry (SphygmoCor; Atcor
Medical, Sydney, Australia). Pressure waveforms were
determined at the right common carotid and right common
femoral arteries. Difference in the time of pulse arrival from
the R-wave of the ECG between the two sites (transit time)
was determined with the intersecting tangents algorithm.
The pulse wave travel distance was calculated as 80% of the
direct straight distance (measured with an infantometer)
between the two arterial sites. The median of three conse-
cutive cfPWV (defined as travelled distance/transit time)
recordings was used in the analyses.
Local arterial elastic properties
Measurements were done at the left common carotid (10mm
proximal to the carotidbulb), the right common femoral (10–
20mm proximal to the flow divider) and the right brachial
(20mm proximal to the antecubital fossa) arteries, with the
use of an ultrasound scanner equipped with a 7.5-MHz linear
probe (MyLab 70; Esaote Europe B.V., Maastricht, The
Netherlands). This setup enables the measurement of diam-
eter, distension and intima–media thickness (IMT) as
described previously [20,21]. Briefly, during the ultrasound
measurements a B-mode image on the basis of 19 M-lines
was depicted on screen and an online echo-tracking algo-
rithm showed real-time anterior and posterior arterial wall
displacements. The M-mode recordings were composed of
19 simultaneous recordings at a frame rate of 498Hz. The
distance between the M-line recording positions was
0.96mm, thus, a total segment of 18.24mm of each artery
was covered by the scan plane. For offline processing, the
radiofrequency signal was fed into a dedicated personal
computer-based acquisition system (ART.LAB; Esaote
Europe B.V.) with a sampling frequency of 50MHz Data
processing was performed in MatLab (version 7.5; Math-
works, Natick, Massachusetts, USA). The distension wave-
forms were obtained from the radio frequency data with the
use of a wall track algorithm [20]. Carotid IMT was defined as
the distance of the posterior wall from the leading edge
interface between lumen and intima to the leading edge
interface between media and adventitia [21]. The median
diameter, distension and IMT of three measurements were
used in the analyses. Local arterial elastic properties were
quantified by calculating the following indices [22]:
(1) Distensibility coefficient (DC)
DC ¼ 2DD  D þDD
2ð Þ
PP D2ð Þ 10
3 kPa1
 
(2) Young’s elastic modulus (YEM) (carotid artery only)
YEM ¼ D
IMT DCð Þ 10
3 kPa
 
where D is arterial diameter; DD distension; IMT intima–
media thickness; and PP brachial pulse pressure (calculated
as SBPDBP).
Distensibility coefficient represents arterial stiffness;
YEM, the stiffness of the arterial wall material at operating
pressure. Note that higher values of cfPWV and YEM, but
lower values of distensibility coefficient reflect greater
arterial stiffness. To make the interpretation of the different
indices comparable, the regression coefficients in our mod-
els (below) of distensibility coefficient were multiplied by
1. Therefore, for all arterial stiffness indices, a positive
regression coefficient signifies increasing arterial stiffness.
Reproducibility
Reproducibility was assessed in 12 individuals (six men;
60.8 6.8 years; six T2D) who were examined by two
observers at two occasions spaced 1 week apart. The
intraobserver and interobserver intraclass correlation coef-
ficients were for cfPWV 0.87 and 0.69, respectively; for
carotid distensibility coefficient 0.85 and 0.73, respectively;
and for YEM 0.72 and 0.71, respectively.
Covariates
Weight and height were measured without shoes and
wearing light clothing using a scale and stadiometer to
the nearest 0.5 kg or 0.1 cm (Seca, Hamburg, Germany).
BMI was calculated by dividing the weight in kilogram by
the height in meters squared. CVD history, smoking status
and diabetes duration were assessed by questionnaire.
Participants were regarded as having a history of CVD if
they reported to have had a MI, and/or cerebrovascular
infarction or haemorrhage, and/or percutaneous artery
angioplasty of/or vascular surgery on the coronary, abdom-
inal, peripheral or carotid arteries. Use of lipid-modifying
and antihypertensive medication was assessed during a
medication interview where generic name, dose and fre-
quency were registered. Insulin use in the 6 months before
the first visit was determined based on the pharmacy
dispensing data using ATC code [17] A10A. Glycated hae-
moglobin A1c (HbA1c), total and HDL cholesterol and
triglycerides were determined as described elsewhere
[16]. Glomerular filtration rate was estimated according to
the Chronic Kidney Disease Epidemiology Collaboration
equation based on the combination of serum creatinine and
serum cystatin C [23]. Office blood pressure (BP) was
determined using a noninvasive BP measurement device
(Omron 705IT; Omron, Kyoto, Japan). MAP was calculated
using the office BP measurements and defined as:
(SBPþ 2DBP)/3.
Statistical analysis
Linear regression analyses were used to study the associ-
ations between metformin use and cfPWV, distensibility
coefficient and YEM, as compared with nonmetformin use.
All arterial stiffness indices were log transformed because of
skewed distributions. Metformin use was stratified accord-
ing to cumulative dose, continuous duration of use, average
daily dose and time since first prescription.
We first adjusted the models for age and sex (covariates
of model 1). In model 2, the following covariates were
Metformin use and arterial stiffness in type 2 diabetics
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added: MAP, BMI, smoking, history of CVD, use of antihy-
pertensive medication and use of lipid modifying drugs.
Moreover, HbA1c, diabetes duration, and use of insulin
were added to adjust for severity of diabetes.
In addition, two sensitivity analyses were performed.
First, we restricted the main analysis to patients with a
cfPWV more than 10.0. As those patients are expected to
have more vascular alterations which may affect the results.
In the second, sensitivity analysis we further adjusted the
main analysis for BP control, defined as an office BP less
than 140/90mmHg.
Furthermore, we compared our cfPWV data with the
published BP corrected age-matched reference data [24].
A P value less than 0.05 was considered statistically
significant. All analyses were done with SAS 9.4 (SAS
Institute Inc., Cary, North Carolina, USA).
RESULTS
In total 672 participants with T2D and pharmacy dispensing
data were available for the current analyses. Due to missing
values on covariates 43 patients were excluded (missing
data on BMI (n¼ 2), smoking (n¼ 26), history of CVD
(n¼ 38), use of antihypertensive medication (n¼ 1), use
of lipid-modifying drugs (n¼ 1) and HbA1c (n¼ 2). These
missing data were not mutually exclusive. Furthermore,
when studying cfPWV, 122 participants were excluded
due to missing values for cfPWV (due to logistic or technical
reasons) which resulted in a study population of 507
participants (453 metformin users and 54 nonmetformin
users). Data from 530 participants was available when
studying distensibility coefficient and data from 529 partic-
ipants when investigating YEM.
In Table 1, the baseline characteristics of the study
population are shown. Metformin users were less often
women (29.4 and 40.7%, respectively), used more often
lipid-modifying drugs (82.8 versus 70.4%) and had on
average a shorter duration of diabetes (5.6 versus 7.4 years)
as compared with nonmetformin users.
Metformin use and carotid-to-femoral pulse
wave velocity
After adjustment for age and sex (covariates of model 1),
MAP, BMI, smoking, prior CVD, the use of antihypertensive
medication, the use of lipid-modifying medication, HbA1c,
diabetes duration and current insulin use (extra covariates
in model 2), metformin use was not statistically significantly
associated with lower aortic stiffness, as estimated by
cfPWV [regression coefficient (b) and 95% confidence
interval: 0.04 (0.11 to 0.02); Table 2; row metformin
use (nonmetformin use is reference category)].
If we analysed metformin use according to cumulative
dose in grams (categories>0–1023, 1024–3121 and3122)
the results showed that, after adjustment for the covariates
of model 2, aortic stiffness, as estimated by cfPWV, was not
statistically associated with the different categories of cumu-
lative metformin dose Table 2; row cumulative dose).
Similar results were obtained if metformin use was
analysed according to continuous duration of use (in days),
average daily dose (in grams) or time since first prescription
(in years).
Metformin use and carotid stiffness indices
After adjustment for age and sex (covariates of model 1) and
MAP, BMI, smoking, prior CVD, use of antihypertensive
medication, and/or use of lipid-modifying medication,
HbA1c, diabetes duration, and current insulin use (extra
covariates of model 2) metformin use was statistically
significantly associated with higher carotid stiffness as
estimated by distensibility coefficient [0.12 (0.01–0.23);
recall 1 multiplication], but not with YEM [0.10 (0.03
to 0.22)] [Table 3; row metformin use (nonmetformin use is
reference category)].
If we analysed metformin use according to cumulative
dose in grams (categories>0–1023, 1024–3121 and3122)
the results showed that, after the adjustments for the cova-
riates of model 2, carotid stiffness as estimated by disten-
sibility coefficient and YEM was associated with greater
stiffness for some of the cumulative dose categories,
whereas there was no association with the highest cumula-
tive dose category.
If we analysed metformin use according to continuous
duration of use in days (categories 0–90, 91–547 and
548), the results showed that, after the adjustments for
the covariates of model 2, carotid stiffness as estimated by
distensibility coefficient and YEM did not decrease with a
longer period of continuous use.
TABLE 1. Baseline characteristics of current metformin and
nonmetformin users
Nonmetformin
users, N¼54
Metformin
users, N¼453
Age, years 62.58.0 62.67.4
Sex (women) 20 (40.7) 133 (29.4)
BMI (kg/m2) 29.04.2 29.54.6
<25 kg/m2 13 (24.1) 71 (15.7)
25–30 kg/m2 19 (35.2) 193 (42.6)
30 kg/m2 22 (40.7) 189 (41.7)
Smoking status
Never 13 (24.1) 127 (28.0)
Former 29 (53.7) 258 (57.0)
Current 12 (22.2) 68 (15.0)
History of cardiovascular disease 17 (31.5) 121 (26.7)
Use of lipid-modifying drugs 38 (70.4) 375 (82.8)
Use of antihypertensive drugs 40 (74.1) 334 (73.7)
eGFR (ml/min per 1.73 m2)a 81.421.4 85.317.1
Total cholesterol to HDL ratio 3.81.3 3.61.1
Triglycerides (mmol/l) 1.81.3 1.70.9
HbA1c (%) 7.71.2 7.01.0
Diabetes duration (years) 7.45.3 5.64.1
Use of insulin in 6 months before
first visit
38 (70.4) 101 (18.6)
Mean arterial pressureb (mmHg) 97.813.6 98.910.3
Office SBP (mmHg) 142.720.8 142.216.8
Office DBP (mmHg) 75.411.8 77.29.4
Office heart rate 70.212.3 72.611.9
cfPWV (m/s) 10.62.5 9.92.3
DCc (10–3 kPa1) 14.44.9 13.14.9
YEMd (103 kPa) 0.70.3 0.80.4
Data are presented as number (%) of patients or mean SD. cfPWV, carotid–femoral
pulse wave velocity; eGFR, estimated glomerular filtration rate; HbA1c, glycated
haemoglobin A1c.
aBased on the CKDEPIcrcys formula, and 452 observations (50 nonmetformin users and
402 metformin users).
bBased on office SBP and DBP measurements.
cBased on 530 observations in total (57 nonmetformin users and 473 metformin users).
dBased on 529 observations in total (57 nonmetformin users and 472 metformin users).
Driessen et al.
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If we analysed metformin use according to average daily
dose in grams (categories 1.0, 1.01–1.80 and 1.81), the
results showed that, after the adjustments for the covariates
of model 2, all average daily dose categories were statisti-
cally significantly associated with greater carotid stiffness as
estimated by distensibility coefficient [0.13 (0.02–0.25), 0.14
(0.03–0.26), 0.15 (0.04–0.27)] but not with YEM; (Table 3;
row average daily dose).
Finally, if we analysed metformin use according to time
since first prescription in years (categories <3.0, 3.0–4.9
and 5.0) the results showed that, after adjustment for the
covariates of model 2, carotid stiffness, as estimated by
distensibility coefficient and YEM, did not decrease with a
longer time since the first prescription.
Sensitivity analyses
Restricting our analysis to participants with a cfPWV more
than 10.0 did not substantially change the results [cfPWV:
0.01 (0.05 to 0.05), distensibility coefficient: 0.12 (0.28 to
0.02), YEM: 0.11 (0.06 to 0.28)]. Adjusting the main
TABLE 3. Current metformin use and carotid artery stiffness indices
Carotid artery distensibility coefficienta Carotid artery young’s elastic modulus
Model 1 Model 2 Model 1 Model 2
N¼530 b (95% CI) b (95% CI) N¼529 b (95% CI) B (95% CI)
Metformin use
No current metformin use 57 Reference Reference 57 Reference Reference
Current metformin use 473 0.12 (0.01 to 0.22) 0.12 (0.01 to 0.23) 472 0.10 (0.02 to 0.21) 0.10 (0.03 to 0.23)
By cumulative dose
0–1023 g 158 0.13 (0.02 to 0.24) 0.18 (0.06 to 0.30) 159 0.10 (0.02 to 0.22) 0.16 (0.02 to 0.29)
1024–3121 g 156 0.12 (0.02 to 0.23) 0.16 (0.05 to 0.27) 155 0.13 (0.01 to 0.25) 0.16 (0.03 to 0.29)
3122 g 159 0.11 (0.00 to 0.22) 0.11 (0.00 to 0.22) 159 0.06 (0.06 to 0.19) 0.06 (0.07 to 0.18)
By continuous duration of use
0–90 days 146 0.11 (0.00 to 0.22) 0.14 (0.03 to 0.26) 146 0.09 (0.03 to 0.21) 0.11 (0.02 to 0.24)
91–547 days 172 0.17 (0.06 to 0.28) 0.21 (0.10 to 0.32) 172 0.16 (0.04 to 0.28) 0.19 (0.06 to 0.31)
548 days 155 0.07 (0.04 to 0.18) 0.09 (0.02 to 0.20) 154 0.05 (0.07 to 0.17) 0.06 (0.06 to 0.19)
By average daily dose
1.0 g/day 166 0.11 (0.00 to 0.21) 0.13 (0.02 to 0.25) 166 0.09 (0.03 to 0.21) 0.10 (0.02 to 0.23)
1.01–1.80 g/day 154 0.11 (0.00 to 0.22) 0.14 (0.03 to 0.26) 153 0.09 (0.03 to 0.22) 0.12 (0.01 to 0.25)
1.81 g/day 153 0.14 (0.04 to 0.25) 0.15 (0.04 to 0.27) 153 0.12 (0.00 to 0.24) 0.12 (0.01 to 0.25)
By time since first metformin prescription
<3.0 years 154 0.12 (0.01 to 0.23) 0.16 (0.04 to 0.28) 154 0.11 (0.01 to 0.23) 0.15 (0.01 to 0.29)
3.0–4.9 years 121 0.08 (0.03 to 0.19) 0.11 (0.02 to 0.23) 120 0.06 (0.06 to 0.19) 0.09 (0.05 to 0.22)
5.0 years 198 0.15 (0.04 to 0.25) 0.15 (0.04 to 0.26) 198 0.11 (0.00 to 0.23) 0.11 (0.02 to 0.23)
CI, confidence interval. Model 1: adjusted for age and sex. Model 2: adjusted for model 1, mean arterial pressure, BMI, smoking, history of cardiovascular disease, use antihypertensive
medication, use of lipid medication, glycated haemoglobin A1c, diabetes duration and use of insulin.
aRegression coefficients of carotid artery distensibility coefficient are multiplied by 1, therefore, for all carotid stiffness indices, a positive regression coefficient signifies increasing
stiffness.
Statistically significant, P value less than 0.05.
TABLE 2. Current metformin use and carotid-to-femoral pulse wave velocity
Model 1 Model2
N¼507 b (95% CI) b (95% CI)
Metformin use
No current metformin use 54 Reference category Reference category
Current metformin use 453 0.07 (0.13 to 0.01) 0.04 (0.11 to 0.02)
By cumulative dose
0–1023 g 150 0.08 (0.14 to 0.02) 0.00 (0.07 to 0.07)
1024–3121 g 149 0.08 (0.14 to 0.01) 0.03 (0.09 to 0.04)
3122 g 154 0.06 (0.13 to 0.00) 0.04 (0.11 to 0.03)
By continuous duration of use
0–90 days 139 0.05 (0.12 to 0.01) 0.00 (0.07 to 0.06)
91–547 days 161 0.09 (0.15 to 0.02) 0.03 (0.10 to 0.04)
548 days 153 0.08 (0.14 to 0.01) 0.04 (0.11 to 0.02)
By average daily dose
1.0 g/day 157 0.08 (0.14 to 0.01) 0.02 (0.09 to 0.05)
1.01–1.80 g/day 147 0.08 (0.15 to 0.02) 0.03 (0.10 to 0.04)
1.81 g/day 149 0.06 (0.12 to 0.01) 0.03 (0.09 to 0.04)
By time since first metformin prescription
<3.0 year 149 0.09 (0.16 to 0.03) 0.04 (0.11 to 0.04)
3.0–4.9 years 114 0.11 (0.18 to 0.05) 0.07 (0.14 to 0.00)
5.0 years 190 0.03 (0.09 to 0.03) 0.01 (0.07 to 0.06)
CI, confidence interval. Model 1: adjusted for age and sex. Model 2: Model 1, mean arterial pressure, BMI, smoking, history of cardiovascular disease, use of antihypertensive
medication, use of lipid-modifying medication and glycated haemoglobin A1c, diabetes duration, and current use of insulin.
Statistically significant, P value less than 0.05.
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analysis for BP control did not materially change the results
[cfPWV: 0.04 (0.10 to 0.03), distensibility coefficient:
0.14 (0.04 to 0.25), YEM: 0.12 (0.00 to 0.23)].
Comparison with reference data
At an individual level the majority (97.8%) of the patients
had a cfPWV which was in the BP corrected age-matched
range (mean 2SD) of the reference values [26]. The other
patients had a cfPWV higher than the BP corrected age-
matched range.
DISCUSSION
The results of the current study show that there is no
association between current metformin use and aortic
stiffness as estimated by cfPWV, regardless of how metfor-
min use was further defined (e.g. by cumulative dose,
average daily dose, continuous duration of use or time
since first prescription). In addition, use of metformin was
not associated with a decrease in carotid stiffness as
assessed by distensibility coefficient and YEM. Counter
intuitively, some individual categories of the metformin
exposure were associated with greater stiffness, however
no consistent pattern with the different stratifications
of metformin use was found. Thereby the results of
the current study do not support the hypothesis that
metformin use protects against CVD by lowering arterial
stiffness.
To the best of our knowledge there is currently no
population-based data available on the association
between use of metformin and arterial stiffness. Interest-
ingly, our population-based data are in line with small
(n 52) clinical trials, which studied short-term use (52
weeks) of metformin and various arterial stiffness param-
eters and showed no effect [25,26].
Our study population was characterized by good gly-
caemic control (mean HbA1c 7.0) and well controlled
hypertension (73.9% of participants used antihypertensive
drugs). As high BP is a prime determinant of arterial
stiffness, the fact that our population was well treated might
have caused an underestimation of the associations
between metformin use and arterial stiffness. In addition,
the majority of our study population had a cfPWV which
was in the BP corrected age-matched range. It may be
suggested that as a result of this there are only relatively
few vascular alterations in our study population, which may
be a reason why we did not found an association between
use of metformin and arterial stiffness.
One of the hypothesized mechanisms how metformin
might decrease arterial stiffness includes via its effect on
AGEs. It has been suggested that metformin might reduce
the AGEs via its antioxidative properties. Metformin treat-
ment (100, 250 and 500 mmol/l) reduced intracellular reac-
tive oxygen species in human aortic endothelial cells [27]. In
addition, use of metformin (60 mg/kg/day) has been asso-
ciated with a reduced production of superoxide and a
reduced level of Ne-(carboxymethyl)lysine, one of the
AGEs, in diabetic rats [28]. Both studies investigated met-
formin concentrations which do not occur in clinical prac-
tice (peak concentration is about 15 mmol/l in humans [29]).
This observation leaves room to speculate whether animal
and in-vitro results could be directly translated to T2D
patients.
An alternative explanation for the fact that we did not
find an association between use of metformin and cfPWV
might be selection bias or confounding by disease severity.
Study participation is voluntary, and it might therefore be
that only relatively healthy patients with T2D, who are
potentially intensively treated for cardiovascular risk fac-
tors, participated (selection bias). Yet, 26.4% of the metfor-
min users still had a history of CVD. Disease severity may
have been an important confounder in this study, as
patients with a poor glycaemic control are often prescribed
higher dosages of metformin and these patients might also
have more arterial stiffness as a consequence of the poor
glycaemic control. We tried to capture disease severity in
our analyses by adjusting for duration of diabetes, use of
insulin, and HbA1c. These adjustments only slightly
changed the point estimates, suggesting that confounding
by disease severity was not an issue in the current study.
Strengths of this study include the availability of longi-
tudinal data on metformin prescriptions, which permitted
us to reliably estimate the average and cumulative dose as
well as the continuous duration of metformin use. In
addition, this made it possible to study long-term use of
metformin and to test our hypothesis in different ways.
Moreover, we have been able to adjust for different impor-
tant confounders. Limitations of this study include a rela-
tively small sample size, which may be the reason we failed
to show an association. Furthermore, only cross-sectional
data were available on the arterial stiffness parameters,
which makes it impossible to examine causal relationships
at this stage.
We showed that dosage and duration of metformin were
not associated with aortic stiffness as measured by cfPWV.
In addition, we showed that metformin dosage and dura-
tion were not associated with lower carotid stiffness as
measured by distensibility coefficient and YEM. The present
results showed no beneficial effect of metformin dosage or
duration on arterial stiffness in middle-aged patients with
T2D using metformin as compared with nonmetformin
users. Alternatively, metformin may exerts its cardio-pro-
tective effects via other pathways, for example, via its
beneficial effects on endothelial dysfunction and(or) low-
grade inflammation [30].
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